Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A-B) the Coherex WaveCrest LAA occlusion system is the latest development in LAA occlusion devices. (A-B) the Coherex WaveCrest LAA occlusion system is.

Published byGwendolyn Holt Modified over 6 years ago

Similar presentations

Presentation on theme: "(A-B) the Coherex WaveCrest LAA occlusion system is the latest development in LAA occlusion devices. (A-B) the Coherex WaveCrest LAA occlusion system is."— Presentation transcript:

1 (A-B) the Coherex WaveCrest LAA occlusion system is the latest development in LAA occlusion devices.
(A-B) the Coherex WaveCrest LAA occlusion system is the latest development in LAA occlusion devices. It consists of a nitinol frame with retractable coils and anchors to enable optimal device positioning. The device consists of a multi-composite membrane including a PTFE membrane on the LA side of the device, and a foam substrate on the LA-opposing surface to minimize residual leaks. Very recently, the WAVECREST I clinical trial was completed - CE Mark approval was obtained in September (C) a cine image showing contrast injection distally of the device (into the LAA) in order to assess complete LAA closure. (D) a TTE image confirming the device is well-seated and without leaks. Some images were presented by Franzen O. on EuroPCR O De Backer et al. Open Heart 2014;1:e000020 ©2014 by British Cardiovascular Society

Download ppt "(A-B) the Coherex WaveCrest LAA occlusion system is the latest development in LAA occlusion devices. (A-B) the Coherex WaveCrest LAA occlusion system is."

Similar presentations

Protecting Against Stroke

Protecting Against Stroke
Update on PFO stents Mark Reisman, M.D., F.A.C.C.

Update on PFO stents Mark Reisman, M.D., F.A.C.C.
Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)

Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)
Examples of three aneurysms treated with stand-alone coiling.

Examples of three aneurysms treated with stand-alone coiling.
Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
(A–C) Sequential angiographic images demonstrating placement of the wire, using the retrograde technique in the LV cavity (A), followed by balloon placement.

(A–C) Sequential angiographic images demonstrating placement of the wire, using the retrograde technique in the LV cavity (A), followed by balloon placement.
Scanning Electron Microscope (SEM) images of the dialysis membranes: cross-section (a) 6 kDa, no polyvinylpyrrolidone (PVP); (b) 12 kDa, 2% PVP; (c) 16 kDa,

Scanning Electron Microscope (SEM) images of the dialysis membranes: cross-section (a) 6 kDa, no polyvinylpyrrolidone (PVP); (b) 12 kDa, 2% PVP; (c) 16 kDa,
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
(A) Image of a stent that was damaged withdrawing it back into a Guideliner V2 after failing to cross the lesion. (A) Image of a stent that was damaged.

(A) Image of a stent that was damaged withdrawing it back into a Guideliner V2 after failing to cross the lesion. (A) Image of a stent that was damaged.
Demonstrating changes in brachial artery diameter, with FMD transient response following cuff deflation at 5 min (frame ∼1800) and sustained NMD response.

Demonstrating changes in brachial artery diameter, with FMD transient response following cuff deflation at 5 min (frame ∼1800) and sustained NMD response.
HOMA calculations where glucose is mmol/L and insulin is mU/L

HOMA calculations where glucose is mmol/L and insulin is mU/L
Hidehiko Hara et al. JIMG 2008;1:92-93

Hidehiko Hara et al. JIMG 2008;1:92-93
(A) Meta-analysis of repeat revascularisation in randomised trials.

(A) Meta-analysis of repeat revascularisation in randomised trials.
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.
Diagnostic modalities on presentation to the emergency room (CT abd/pelvis, CT of the abdomen and pelvis with contrast; CT chest, CT of the chest with.

Diagnostic modalities on presentation to the emergency room (CT abd/pelvis, CT of the abdomen and pelvis with contrast; CT chest, CT of the chest with.
Changes in smoking behaviour over time.

Changes in smoking behaviour over time.

Similar presentations

Ads by Google